Welcome to our dedicated page for Liquidia news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia stock.
Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Summary not available.
Liquidia Corporation (NASDAQ: LQDA) will report its first quarter 2023 financial results on May 4, 2023, at 8:30 a.m. Eastern Time. The company will also provide a corporate update during a webcast, which will be available on its website. Liquidia is focused on developing treatments for pulmonary hypertension and has developed YUTREPIA™, an investigational inhalation powder for pulmonary arterial hypertension (PAH), which received tentative FDA approval in November 2021. For further information, a rebroadcast of the webcast will be available for 30 days following the live event.
Liquidia Corporation (NASDAQ: LQDA) has announced that CFO Michael Kaseta will present a business overview during a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference. The session is scheduled for April 18, 2023, at 11:00 a.m. Eastern Standard Time.
Interested participants can access the live webcast on Liquidia's website, and an archived version will be available for 30 days post-event. Liquidia focuses on developing treatments for pulmonary hypertension and uses its proprietary PRINT® Technology. The company’s investigational product, YUTREPIA™, is aimed at treating pulmonary arterial hypertension.
Liquidia Corporation (NASDAQ: LQDA) announced a new, non-exclusive license agreement with GSK, replacing a prior collaboration from 2012. This agreement allows Liquidia to leverage its PRINT® technology for developing inhaled formulations, excluding certain GSK proprietary molecules. GSK retains a non-exclusive, royalty-free right for pre-clinical research. CEO Roger Jeffs highlighted benefits from restructuring the relationship to enhance product development opportunities. The earlier agreement had granted GSK an exclusive license in inhaled therapeutics, but the new terms require GSK to seek an expanded license for clinical or commercial use.
Liquidia Corporation (NASDAQ: LQDA) reported a net loss of $41 million for the full year ending December 31, 2022, with a revenue increase to $15.9 million from $12.9 million in 2021. The decrease in profit-sharing from its agreement with Sandoz, which fell from 80% to 50%, was countered by an increase in units sold. The company clarified its path to launching YUTREPIA, anticipating legal resolution by mid-2024, and has strengthened its financial position through various financing activities, including a $100 million revenue interest deal. The company's cash reserves increased to $93.3 million.
Liquidia Corporation (NASDAQ: LQDA) will announce its full-year 2022 financial results on March 16, 2023. A live webcast is scheduled for 8:30 a.m. Eastern Time, where the company will discuss its financial outcomes and provide a corporate update.
Liquidia is a biopharmaceutical firm focusing on pulmonary hypertension treatments, utilizing its PRINT® Technology. Its YUTREPIA™ inhalation powder has received tentative FDA approval for pulmonary arterial hypertension (PAH), indicating progress in its product development.
Liquidia Corporation (NASDAQ: LQDA) announced that the PTAB has upheld its decision declaring the ‘793 patent unpatentable, rejecting UTHR's rehearing request. The PTAB clarified that prior art cited by Liquidia was publicly distributed before the filing of the initial patent application. Liquidia anticipates a legal resolution regarding this patent by late 2023 or early 2024. UTHR is expected to appeal the PTAB's decision. If affirmed on appeal, the cancellation of the ‘793 patent will negate UTHR's infringement claims against Liquidia.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options for 10,000 shares to newly hired non-executive employees under its Inducement Plan. Each option, intended as part of the employment compensation, is exercisable at $6.39 per share, the closing price on the grant date of February 1, 2023. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. The Inducement Plan specifically allows for non-statutory stock options for individuals who are new hires or returning after a period of non-employment.
Liquidia Corporation (NASDAQ: LQDA) announced a Revenue Interest Financing Agreement with HealthCare Royalty (HCRx), securing up to $100 million to support the launch of YUTREPIA™ (treprostinil) inhalation powder and other business activities. Liquidia will receive an initial $32.5 million, with additional tranches contingent on conditions like patent litigation outcomes. The agreement is intended to extend Liquidia's cash runway through at least 2024, providing non-dilutive capital while maintaining financial flexibility.
Liquidia Corporation (NASDAQ: LQDA) announced a collaboration with Sandoz and Mainbridge Health Partners to develop a new subcutaneous infusion pump for Treprostinil Injection, a generic version of Remodulin. The Pump Agreement includes equal sharing of development costs and aims for FDA submission in 2023. Additionally, Liquidia and Sandoz extended their promotion agreement for Treprostinil Injection through 2032. This partnership emphasizes Liquidia's commitment to enhance treatment options for pulmonary arterial hypertension (PAH) patients.